HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

    NEXT STORY
    [Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche’s Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
    PREV STORY
    atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    India In Vitro Diagnostics (IVD) Market Outlook, 2025: Fully Automated Systems are Being Adopted, Increasing Number of Phase-III Clinical Trials

    author_avatar
    NASDAQ Market News

    Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020

    author_avatar
    NASDAQ Market News

    Nomination Committee Appointed for the Annual General Meeting 2021 in Immunicum AB (publ)

    author_avatar
    NASDAQ Market News